US/UK/Canada

Share

Contacts

  • Rikard Akhtarzand

    CEO


    Grev Turegatan 3, floor 4, SE 114 46 Stockholm, Sweden
    08 128 766 00
    http://www.addvisegroup.com

    • Quotes

    Strengthening ADDvise with Fredrik Mella enables us to continue to accelerate our growth rate. He will complement our management team with his international experience from the Medtech industry, and I believe Fredrik will be a good leader and coach for our subsidiaries' CEOs.
    Rikard Akhtarzand, CEO
    ADDvise is a successful company in the middle of an exciting growth journey. I look forward to make a difference and contribute with my experiences
    Fredrik Mella
    Pick a time period -
    Tags ( Active)

    ADDvise explores potential divestment of its subsidiary Germa

    ADDvise is exploring the possibility of divesting its subsidiary AB Germa. Germa has shifted its focus primarily towards defense equipment, which falls outside of ADDvise’s core business within life science. ADDvise is therefore evaluating options to find a new owner who can further develop Germa and maximize its full potential within the defense segment. Since ADDvise acquired the company in 2017, Germa has experienced strong growth. At the time of acquisition, Germa had revenues of SEK 30 million with an EBITDA of SEK 3.5 million. As of the rolling twelve-month period ending September

    ADDvise receives order worth USD 1.8 million

    ADDvise Group’s subsidiary MRC Systems has received an order from Orbitworks, a company specialized in advanced technology, based in United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q2 2025. For further information, please contact: Staffan Torstensson, CEO+46 704 33 20 19staffan.torstensson@addvisegroup.se Important information This information is information that ADDvise Group AB is required to

    ADDvise streamlines organization through new business area structure

    To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable knowledge-sharing across the group. The Healthcare business area manufactures and supplies a diverse range of advanced medical technology, high-quality consumables, and pharmaceuticals. By

    Interim report 2024, January 1–September 30

    The third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment for clinical trials, we showed robust development. Excluding these segments, we saw organic growth of 6% for January−September, reflecting the strength of our business. July–September 2024 Net revenue for the period was SEK 403.6 million (321.1), an increase of 25.7% On an organic basis, net revenue declined by 24.6% Orders received for the period was SEK 421.8 million (360.0),

    ADDvise Group’s nomination committee for the Annual General Meeting 2025

    In accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2025 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2024 maintained by Euroclear Sweden, and of the chairman of the board of directors. The representative appointed by the largest shareholder by votes shall be appointed chairman of the nomination committee. The nomination committee has now been appointed and consists of the following members: · Rikard

    Invitation to presentation of interim report July 1 – September 30, 2024

    Media, investors and analysts are invited to attend a presentation of the interim report for the period July 1 – September 30, 2024. The presentation will take place on October 24, 2024, at 14:00 (CEST) / 08:00 AM (EST). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report in a webcast and telephone conference.   Webcast If you wish to participate via webcast, please use the link below. https://ir.financialhearings.com/addvise-group-q3-report-2024   Conference call If you wish to participate via teleconference, please register on the link

    ADDvise receives order worth USD 1.3 million

    ADDvise Group’s subsidiary MRC Systems has received an order from Medisept. The company is a medical device manufacturer for the healthcare industry based in Oran, Algeria. The order is worth approximately USD 1.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new medical device manufacturing facility with approximately 700m2 of production area located in Oran, Algeria. Delivery of the order is scheduled to be completed during Q2 2025.  For further information, please contact: Staffan Torstensson, CEO+46 704 33 20

    ADDvise receives order worth SEK 32.5 million

    ADDvise Group’s subsidiary Germa has received an order from Saab AB (publ). The order has a total value of approximately SEK 32.5 million. The order relates to the delivery of equipment and related components. The deliveries will be separated and are expected to be made during 2025 as agreed between Germa and Saab. Payment will be made after delivery. Germa develops, markets and manufactures quality products within rescue, ambulance, health care and rehabilitation. For further information, please contact: Staffan Torstensson, CEO+46 704 33 20 19staffan.torstensson@

    Fredrik Celsing appointed new chairman of the board of directors as of 1 September – extraordinary general meeting on 29 August cancelled

    ADDvise Group AB has previously convened an extraordinary general meeting on 29 August 2024 to elect a new board member. Major shareholders in the company, who together represent approximately 30 percent of the shares in the company, have proposed that a new board member shall be elected to the board of directors to replace Staffan Torstensson, who will take over as CEO of ADDvise Group AB on 1 September 2024. Following discussions between the proposers and Kenneth Lindqvist, who as soon as an FDI notification is approved will become the largest shareholder in the company, the proposal in

    Chairman of the board and incoming CEO of ADDvise divests shares of series A and acquires shares of series B

    The chairman of the board and incoming CEO Staffan Torstensson has today, privately and through companies, divested 610,000 shares of series A to Kenneth Lindqvist, one of the major shareholders of ADDvise, privately and through companies. The total purchase price for the shares amounted to SEK 9,150,000. In conjunction with the divestment of the shares of series A, Staffan Torstensson has acquired 1,500,000 shares of series B in ADDvise at a price of SEK 5.86 per share. After the transactions, Staffan Torstensson’s holdings, privately and through companies, will amount to 4,816,660

    Departing CEO of ADDvise divests shares of series A to a major shareholder of ADDvise

    The departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate of Strategic Products (ISP) pursuant to the Screening of Foreign Direct Investments Act (2023:560), and will be completed after the obtaining of such approval. Upon completion of the transaction, Rikard Akhtarzand’s holdings, privately and

    Interim report 2024, January 1 – June 30

    The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second half of the year. April – June 2024 Net revenue for the period was SEK 412.3 million (344.4), an increase of 19.7% On an organic basis, net revenue declined by 20.6% Orders received for the period was SEK 534.0 million (

    Notice to extraordinary general meeting of ADDvise Group AB (publ)

    ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the extraordinary general meeting on 29 August 2024 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST.   NOTIFICATION Shareholders wishing to attend the general meeting must:   i)          be registered in the share register kept by Euroclear Sweden AB on the record date 21 August 2024, or, if the shareholder has had his/her shares registered in the name of a nominee, request that the nominee registers the shares for voting purposes in such time that the registration is

    Staffan Torstensson is appointed new CEO of ADDvise. The CFO and incoming CEO is leaving

    The board of directors of ADDvise Group announces today that the chairman of the board, Staffan Torstensson, is appointed CEO of the company, effective September 1, 2024. In light of this transition, the board will convene an extraordinary general meeting in the near future to elect Per Åhlgren as board member and new chairman of the board of directors, effective October 1, 2024. The current CEO and board member Rikard Akhtarzand will serve as interim chairman of the board from September 1, 2024, until the new chairman assumes office on October 1, 2024. Staffan Torstensson will step down

    Invitation to presentation of interim report January 1 – June 30, 2024

    ADDvise Group’s interim report for the period January 1 – June 30, 2024 will be published on July 18, 2024 at 07:45 (CEST).   Investors, analysts, and other stakeholders are invited to a webcast and conference call at 14:00 (CEST) / 08:00 AM (EST) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will present the report.   Webcast If you wish to participate via webcast, please use the link below.   https://ir.financialhearings.com/addvise-group-q2-report-2024/register   Conference call If you wish to participate via conference call, please register

    ADDvise receives order worth USD 1.4 million

    Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and rental of medical and laboratory equipment. The order value amounts to USD 1.4 million. Delivery will take place over a four-year period starting in Q3 2024.   For further information, please contact: Rikard Akhtarzand, CEO +46 (0) 76-525 90 71 rikard.akhtarzand@addvisegroup.se   Important information This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The

    ADDvise Group plans to change listing venue to Nasdaq Stockholm main market

    ADDvise Group AB (publ) ("ADDvise Group") has initiated the process of listing the company's A and B shares on Nasdaq Stockholm. The change of listing venue is expected to be completed in the first quarter of 2025. As part of the continued development of ADDvise Group, the company has for some time reviewed the possibility of changing its listing venue from Nasdaq First North to Nasdaq Stockholm main market. The Board of Directors believes that a change of listing venue would be beneficial for the company's continued development, provide a broader capital allocation toolkit, and increase

    Report from the annual general meeting of ADDvise Group AB (publ) on 3 May 2024

    ADDvise Group AB (publ), reg. no. 556363-2115, has held its annual general meeting on 3 May 2024 at 10 a.m. CEST at the company’s premises at Grev Turegatan 30 in Stockholm. At the meeting it was resolved on, among other things, re-election of Staffan Torstensson, Fredrik Celsing, Johanne Brændgaard and Anna Ljung as board members, new election of Thomas Eklund and Rikard Akhtarzand as board members, re-election of Öhrlings PricewaterhouseCoopers AB as the auditor of the company, adoption of new guidelines for remuneration to senior executives and new articles of association, as well as an

    Oliver Humlen is appointed new CEO of ADDvise Group, succeeding Rikard Akhtarzand who will transition to a board and active shareholder role

    ADDvise Group has appointed Oliver Humlen as new CEO, effective September 1, 2024. He will succeed Rikard Akhtarzand who will take up the position as CEO of Your.Online, a European serial acquirer platform backed by Strikwerda Investments.   Rikard will remain a significant and long-term shareholder in ADDvise Group and is nominated to the Board of Directors by the Group’s largest shareholder, Per Åhlgren, and Chairman of the Board and shareholder, Staffan Torstensson, at the annual general meeting on May 3, 2024.   “Constellation Software Inc. and Topicus.com have been two of

    ADDvise receives order worth USD 11.3 million

    MRC Systems, an ADDvise Group company, has received an order from leading Omani biopharmaceutical company Opal Bio Pharma. The initial order value amounts to USD 11.3 million with an extension option amounting to an additional USD 6.8 million.   The order involves the design, supply, installation and validation of cleanroom panelling, HVAC and accessories for a biopharmaceutical production and R&D facility based outside Muscat, Oman. The project is scheduled for completion by the end of 2025.   “One of the Group’s largest orders to date, this exciting project further cements MRC’

    ADDvise publishes prospectus and applies for admission to trading of bonds on Nasdaq Stockholm

    On 4 April 2024, ADDvise Group AB (publ) (“ADDvise”) issued senior secured bonds in an amount of USD 60 million, under a total framework of USD 200 million (the “Bonds”). Pursuant to the terms and conditions for the Bonds, ADDvise has undertaken to apply for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm. For this purpose, the company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the company’s website www.addvisegroup.com and at the

    Interim report 2024, January 1 – March 31

    The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved.January – March 2024 Net revenue for the period was SEK 413.4 million (310.5), an increase of 33.1% On an organic basis, net revenue declined by 9.5%. Excluding pharmaceuticals, organic growth was 3.6%. EBITDA for the period was SEK 99.1 million (84.2) Profit/loss

    ADDvise receives allocation decision worth EUR 1.25 million

    ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025.   The allocation decision is subject to a customary appeals period.   For further information, please contact: Rikard Akhtarzand, CEO +46 (0) 76-525 90 71 rikard.akhtarzand@addvisegroup.se   Important information This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe